The Promise and Peril of Precision Medicine: Phenotyping Still Matters Most

Mayo Clinic Proceedings

Volumn 91, Issue 11, 2016, Pages 1606-1616

  Ackerman, Jaeger P ^a,b   Bartos, Daniel C ^c,d   Kapplinger, Jamie D ^a,b   Tester, David J ^a,b   Delisle, Brian P ^c   Ackerman, Michael J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMIN; DNA; POTASSIUM CHANNEL KCNQ1;

AUTOPSY; ELECTROCARDIOGRAPHY; EXOME; GENE IDENTIFICATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; HETEROLOGOUS EXPRESSION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KCNQ1 GENE; LONG QT SYNDROME; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; SUDDEN DEATH;

EID: 84994441567     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.08.008     Document Type: Review

References (32)

1. 1 Kong, M.H., Fonarow, G.C., Peterson, E.D., et al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol 57:7 (2011), 794–801.
2. 2 Mehra, R., Global public health problem of sudden cardiac death. J Electrocardiol 40:6 (2007), S118–S122.
3. 3 Kung, H.C., Hoyert, D.L., Xu, J., Murphy, S.L., Deaths: final data for 2005. Natl Vital Stat Rep 56:10 (2008), 1–120.
4. 4 Tester, D.J., Ackerman, M.J., Cardiomyopathic and channelopathic causes of sudden unexplained deaths in infants and children. Annu Rev Med 60 (2009), 69–84.
5. 5 Tester, D.J., Ackerman, M.J., The molecular autopsy; should the evaluation continue after the funeral?. Pediatr Cardiol 33:3 (2012), 461–470.
6. 6 Skinner, J.R., Duflou, J.A., Semsarian, C., Reducing sudden death in young people in Australia and New Zealand: the TRAGADY initiative. Med J Aust 189:10 (2008), 539–540.
7. 7 Ackerman, M.J., Priori, S.G., Willems, S., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm 8:8 (2011), 1308–1339.
8. 8 Priori, S.G., Wilde, A.A., Horie, M., et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm 10:12 (2013), 1932–1963.
9. 9 Tester, D.J., Will, M.L., Ackerman, M.J., Mutation detection in congenital long QT syndrome: cardiac channel gene screen using PCR, dHPLC, and direct DNA sequencing. Methods Mol Med 128 (2006), 181–207.
10. 10 Bartos, D.C., Duchatelet, S., Burgess, D.E., et al. R231C mutation in KCNQ1 causes long QT syndrome type 1 and familial atrial fibrillation. Heart Rhythm 8:1 (2011), 48–55.
11. 11 Sanguinetti, M.C., Curran, M.E., Zou, A., et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 384:6604 (1996), 80–83.
12. 12 Narula, N., Tester, D.J., Paulmichl, A., Maleszewski, J.J., Ackerman, M.J., Post-mortem whole exome sequencing with gene-specific analysis for autopsy-negative sudden unexplained death in the young: a case series. Pediatr Cardiol 36:4 (2015), 768–778.
13. 13 Anderson, J.H., Tester, D.J., Will, M.L., Ackerman, M.J., Whole exome molecular autopsy following exertion-related sudden unexplained death in the young. Circ Cardiovasc Genet 9 (2016), 259–265.
14. 14 Richards, S., Aziz, N., Bale, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:5 (2015), 405–424.
15. 15 Cerrone, M., Napolitano, C., Priori, S.G., Catecholaminergic polymorphic ventricular tachycardia: a paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation. Heart Rhythm 6:11 (2009), 1652–1659.
16. 16 Kapplinger, J.D., Pundi, K., Callis, T.E., et al. Refining genetic test interpretation for ryanodine receptor-mediated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 13:5 (2016), A1–A8 S1–S688.
17. 17 Goldfarb, L.G., Park, K.Y., Cervenakova, L., et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 19:4 (1998), 402–403.
18. 18 Dalakas, M.C., Park, K.Y., Semino-Mora, C., et al. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 342:11 (2000), 770–780.
19. 19 He, Y., Zhang, Z., Hong, D., Dai, Q., Jiang, T., Myocardial fibrosis in desmin-related hypertrophic cardiomyopathy. J Cardiovasc Magn Reson, 12(1), 2010, 68.
20. 20 Bär, H., Goudeau, B., Wälde, S., et al. Conspicuous involvement of desmin tail mutations in diverse cardiac and skeletal myopathies. Hum Mutat 28:4 (2007), 374–386.
21. 21 Brodehl, A., Hedde, P.N., Dieding, M., et al. Dual color photoactivation localization microscopy of cardiomyopathy-associated desmin mutants. J Biol Chem 287:19 (2012), 16047–16057.
22. 22 Otten, E., Asimaki, A., Maass, A., et al. Desmin mutations as a cause of right ventricular heart failure affect the intercalated disks. Heart Rhythm 7:8 (2010), 1058–1064.
23. 23 Ackerman, M.J., Genetic purgatory and the cardiac channelopathies: exposing the variants of uncertain/unknown significance issue. Heart Rhythm 12:11 (2015), 2325–2331.
24. 24 Semsarian, C., Ingles, J., Wilde, A.A., Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. Eur Heart J 36:21 (2015), 1290–1296.
25. 25 Van Driest, S.L., Wells, Q.S., Stallings, S., et al. Association of arrhythmia-related genetic variants with phenotypes documented in electronic medical records. JAMA 315:1 (2016), 47–57.
26. 26 Ackerman, M.J., Tester, D.J., Jones, G.S., et al. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 78:12 (2003), 1479–1487.
27. 27 Ackerman, M.J., Splawski, I., Makielski, J.C., et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 1:5 (2004), 600–697.
28. 28 Kapa, S., Tester, D.J., Salisbury, B.A., et al. Genetic testing for long QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 120:18 (2009), 1752–1760.
29. 29 Refsgaard, L., Holst, A.G., Sadjadieh, G., et al. High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet 20:8 (2012), 905–908.
30. 30 Boycott, K.M., Vanstone, M.R., Bulman, D.E., MacKenzie, A.E., Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14:10 (2013), 681–691.
31. 31 Kohane, I.S., Masys, D.R., Altman, R.B., The incidentalome: a threat to genomic medicine. JAMA 296:2 (2006), 212–215.
32. 32 Green, R.C., Berg, J.S., Grody, W.W., et al. ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing. Genet Med 15:7 (2013), 565–574.